Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The pharmacokinetics and pharmacogenetics of the antiemetic cyclizine in palliative care patients.

Journal of pain and symptom management - 1 Mar 2012

Vella-Brincat Jane W A, Begg Evan J, Jensen Berit P, Chin Paul K L, Roberts Rebecca L, Fairhall Mary, Macleod Sandy A D, Reid Kate

Abstract excerpt

CONTEXT: Cyclizine, an antihistaminic antiemetic, is commonly used in palliative care. Its pharmacokinetics have been poorly studied, and its metabolic pathway is unknown but may involve the genetically controlled cytochrome P450 2D6 (CYP2D6). If this is the case, the metabolic ratio of cyclizine to norcyclizine and efficacy/adverse effects may vary between patients according to their CYP2D6 genotype. OBJECTIVES:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to Chromatography, High Pressure Liquid

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2D6

Share to Dose-Response Relationship, Drug

Share to Half-Life

Share to Palliative Care

Share to Pharmacogenetics

Share to Tandem Mass Spectrometry

Source

Identifiers

PMID: 22209223
DOI: 10.1016/j.jpainsymman.2011.04.022

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The pharmacokinetics and pharmacogenetics of the antiemetic cyclizine in palliative care patients.PMID 22209223Read ↗

PharmGKB summary: carbamazepine pathway.Semantic proximity Read ↗

PharmGKB summary: citalopram pharmacokinetics pathway.Semantic proximity Read ↗

CYP2D6 phenotype-specific codeine population pharmacokinetics.Semantic proximity Read ↗

Does pharmacogenomics account for variability in control of acute chemotherapy-induced nausea and vomiting with 5-hydroxytryptamine type 3 receptor antagonists?Semantic proximity Read ↗

Pharmacogenetic considerations with dichloroacetate dosing.Semantic proximity Read ↗

CYP2A6 genetic variation and dexmedetomidine disposition.Semantic proximity Read ↗

Influence of CYP2D6 Polymorphism on the Pharmacokinetic/Pharmacodynamic Characteristics of Carvedilol in Healthy Korean Volunteers.Semantic proximity Read ↗

PharmGKB summary: tramadol pathway.Semantic proximity Read ↗

Phase 1 study to investigate the pharmacokinetic properties of dacomitinib in healthy adult Chinese subjects genotyped for CYP2D6.Semantic proximity Read ↗

Effect of SLC22A1 polymorphism on the pharmacokinetics of proguanil in Korean: A semi-physiologic population pharmacokinetic approach.Semantic proximity Read ↗

PharmGKB summary: lamotrigine pathway, pharmacokinetics and pharmacodynamicsSemantic proximity Read ↗

Relationship of CYP2D6, CYP3A, POR, and ABCB1 genotypes with galantamine plasma concentrations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.